Skip to main content

Bitterman Kevin's Form 4 filing

Disc Medicine, Inc.IRON · filed Sep 3, 2026

Accession no.
0001591747-26-000002
Filed
Sep 3, 2026, 5:43 PM ET
Trade date
Sep 1-3, 2026
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 12 non-derivative transactions. Open-market sales total $4.37M. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Bitterman KevinCIK 0001591747Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 1, 2026Common StockSSaleDisposed−70$79.95−$5,596.5349,140Indirect
Sep 1, 2026Common StockSSaleDisposed−58$79.95−$4,637.1337,427Indirect
Sep 1, 2026Common StockSSaleDisposed−1$79.95−$79.9514,012Indirect
Sep 2, 2026Common StockSSaleDisposed−26,542$80.17F5−$2,127,872.14322,598Indirect
Sep 2, 2026Common StockSSaleDisposed−22,090$80.17F5−$1,770,955.3315,337Indirect
Sep 2, 2026Common StockSSaleDisposed−511$80.17F5−$40,966.8713,501Indirect
Sep 2, 2026Common StockSSaleDisposed−10$80.98F6−$809.8322,588Indirect
Sep 2, 2026Common StockSSaleDisposed−9$80.98F6−$728.82315,328Indirect
Sep 2, 2026Common StockSSaleDisposed−2$80.98F6−$161.9613,499Indirect
Sep 3, 2026Common StockSSaleDisposed−2,810$79.98F7−$224,743.8319,778Indirect
Sep 3, 2026Common StockSSaleDisposed−2,339$79.98F7−$187,073.22312,989Indirect
Sep 3, 2026Common StockSSaleDisposed−54$79.98F7−$4,318.9213,445Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F5

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.95 to $80.9421 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 3 transactions in Table I.

F6

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $80.9677 to $81.0079 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 3 transactions in Table I.

F7

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.95 to $80.28 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 3 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)